JAGUAR HEALTH, INC. Accumulated Other Comprehensive Income
JAGUAR HEALTH, INC. (JAGX) had Accumulated Other Comprehensive Income of -$1.24 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-19
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.24M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.24M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$833.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$839.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$1.24M 10-Q · filed 2026-08-19 |
| 2026-03-31 | -$1.24M 10-Q · filed 2026-05-20 |
| 2025-12-31 | -$833.00K 10-Q · filed 2026-08-19 |
| 2025-09-30 | -$839.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$719.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$700.00K 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$467.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | -$687.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$542.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$461.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$652.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$796.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$723.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$884.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$680.00K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |